{
    "nctId": "NCT00896376",
    "briefTitle": "Trastuzumab in Treating Women With Metastatic Breast Cancer",
    "officialTitle": "Prospective Multicenter Study of Genetic Factors Predictive of the Pharmacodynamics of Trastuzumab in Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 49,
    "primaryOutcomeMeasure": "Toxicity, including cardiotoxicity and immuno-allergic reactions",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Metastatic disease, defined by the existence of a secondary tumor localization radiologically (i.e., by radiography, CT scan, MRI scan, or ultrasound) or scintigraphically confrimed\n* Evaluable disease\n* Beginning first-line metastatic treatment with trastuzumab (Herceptin\u00ae) with or without chemotherapy\n* Primary tumor must overexpress HER2 (IHC 3+ OR IHC 2+ and FISH+ OR FISH+)\n* Hormone receptor status not specified\n* No brain metastasis\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Life expectancy \\> 3 months\n* Able to undergo cardiotoxicity evaluation every 4 months by measuring LVEF via an isotopic method or ultrasound with systematic registration\n* No chronic uncontrolled disease\n* No heart failure\n* No respiratory failure or hypoxemia\n* No history of another primary cancer except for basal cell carcinoma of the skin\n* No severe uncontrolled infection\n* No psychological incapacity\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}